Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly

International Journal of Cancer

Volumn 125, Issue 9, 2009, Pages 2122-2126

  Theodoropoulou, Marily ^a   Tichomirowa, Maria A ^b   Sievers, Caroline ^a   Yassouridis, Alexander ^a   Arzberger, Thomas ^c   Hougrand, Olivier ^b   Deprez, Manuel ^b   Daly, Adrian F ^b   Petrossians, Patrick ^b   Pagotto, Uberto ^d   Beckers, Albert ^b   Stalla, Günter K ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acromegaly; Resistance; Somatostatin analogs; Tumor shrinkage; ZAC1

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; PROTEIN ZAC1; SOMATOMEDIN C; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; CYCLOPEPTIDE; DRUG DERIVATIVE; HUMAN GROWTH HORMONE; PLAGL1 PROTEIN, HUMAN; SOMATOSTATIN; TRANSCRIPTION FACTOR;

ACROMEGALY; ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHYSIS TUMOR; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; TREATMENT RESPONSE; ADOLESCENT; BLOOD; CHEMISTRY; COHORT ANALYSIS; MIDDLE AGED; RETROSPECTIVE STUDY;

ACROMEGALY; ADOLESCENT; ADULT; AGED; CELL CYCLE PROTEINS; COHORT STUDIES; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; RETROSPECTIVE STUDIES; SOMATOSTATIN; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 70249133387     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24602     Document Type: Article

References (38)

1. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2003;2:999-1017. (Pubitemid 37540581)
2. Melmed S. Acromegaly. N Engl J Med 2006;355:2558-2573
3. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008;93:61-67
4. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of liege. Belgium. J Clin Endocrinol Metab 2006;91:4769-4775 (Pubitemid 44917305)
5. Schneider HJ, Sievers C, Saller B, Wittchen HU, Stalla GK. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf) 2008;69:432-435
6. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90:4465-4473 (Pubitemid 41159328)
7. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006;91:1397-1403
8. Stevenaert A, Beckers A. Presurgical octreotide: treatment in acromegaly. Metabolism 1996;45(8 Suppl 1):72-74
9. Beckers A. Does preoperative somatostatin analog treatment improve surgical cure rates in acromegaly? A new look at an old question. J Clin Endocrinol Metab 2008;93:2975-2977
10. Bevan JS. The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005;90:1856-1863 (Pubitemid 40464061)
11. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005;90:4405-4410 (Pubitemid 41058228)
12. Besser GM, Burman P, Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol 2005;153:187-193 (Pubitemid 41167474)
13. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family. Life Sci 1995;57:1249-1265
14. Cheung NW, Boyages SC. Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block. Endocrinology 1995;136:4174-4181
15. Srikant CB. Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituitary cells. Biochem Biophys Res Commun 1995;209:400-406
16. Sharma K, Srikant CB. Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 1998;76:259-266 (Pubitemid 28180381)
17. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, Pagotto U, Stalla GK. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 2006;66:1576-1582 (Pubitemid 43259940)
18. Pagotto U, Arzberger T, Theodoropoulou M, Grübler Y, Pantaloni C, Saeger W, Losa M, Journot L, Stalla GK, Spengler D. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res 2000;60:6794-6799 (Pubitemid 32059140)
19. Spengler D, Villalba M, Hoffmann A, Pantaloni C, Houssami S, Bockaert J, Journot L. Regulation of apoptosis and cell cycle arrest by Zac1, a novel zinc finger protein expressed in the pituitary gland and the brain. EMBO J 1997;16:2814-2825 (Pubitemid 27226218)
20. Varrault A, Gueydan C, Delalbre A, Bellmann A, Houssami S, Aknin C, Severac D, Chotard L, Kahli M, Le Digarcher A, Pavlidis P, Journot L. Zac1 regulates an imprinted gene network critically involved in the control of embryonic growth. Dev Cell 2006;11:711-722 (Pubitemid 44752557)
21. Pagotto U, Arzberger T, Ciani E, Lezoualc'h F, Pilon C, Journot L, Spengler D, Stalla GK. Inhibition of Zac1, a new gene differentially expressed in the anterior pituitary increases cell proliferation. Endocrinology 1999;140:987-996
22. Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R. Partial surgical removal of growth hormone- secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2006;91:85-92. (Pubitemid 43069122)
23. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 2005;90:6290-6295 (Pubitemid 41606558)
24. Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, Papotti M, Mangili F, Terreni MR, Camanni F, Giovanelli M. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab 2001;86:5194-5200 (Pubitemid 33070235)
25. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996;10:1688-1696 (Pubitemid 26408756)
26. Ferrante E, Pellegrini C, Bondioni S, Peverelli E, Locatelli M, Gelmini P, Luciani P, Peri A, Mantovani G, Bosari S, Beck-Peccoz P, Spada A, et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer 2006;13:955-962 (Pubitemid 44767383)
27. Ezzat S, Horvath E, Harris AG, Kovacs K. Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab 1994;79:113-118 (Pubitemid 24221169)
28. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes- Socin H, Stevenaert A, Chanson P, Beckers A. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005;152:61-66 (Pubitemid 40185454)
29. Picard C, Silvy M, Gerard C, Buffat C, Lavaque E, Figarella-Branger D, Dufour H, Gabert J, Beckers A, Brue T, Enjalbert A, Barlier A. Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment. Int J Cancer 2007;121:1245-1252 (Pubitemid 47293791)
30. Reubi JC, Landolt AM. The growth-hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab 1989;68:844-850
31. Bertherat J, Chanson P, Dewailly D, Enjalbert A, Jaquet P, Kordon C, Peillon F, Timsit J, Epelbaum J. Resistance to somatostatin (SRIH) analog therapy in acromegaly. Re-evaluation of the correlation between the SRIH receptor status of the pituitary tumor and the in vivo inhibition of GH secretion in response to SRIH analog. Horm Res 1992;38:94-99
32. Broson-Chazot F, Houzard C, Ajzenberg C, Nocaudie M, Duet M, Mundler O, Marchandise X, Epelbaum J, Gomez De Alzaga M, Schäfer J, Meyerhof W, Sassolas G, et al. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide. Clin Endocrinol (Oxf) 1997;47:589-598 (Pubitemid 27496334)
33. Barlier A, Pellegrini-Bouiller I, Gunz G, Zamora AJ, Jaquet P, Enjalbert A. Impact of gsp oncogene on the expression of genes coding for Gsα, Pit-1, Gi2α, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J Clin Endocrinol Metab 1999;84:2759-2765 (Pubitemid 30642008)
34. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik LH. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 2000;85:781-792 (Pubitemid 32273669)
35. Takei M, Suzuki M, Kajiya H, Ishii Y, Tahara S, Miyakoshi T, Egashira N, Takekoshi S, Sanno N, Teramoto A, Osamura RY. Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide. Endocr Pathol 2007;18:208-216
36. Acunzo J, Thirion S, Roche C, Saveanu A, Gunz G, Germanetti AL, Couderc B, Cohen R, Figarella-Branger D, Dufour H, Brue T, Enjalbert A, et al. Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas. Cancer Res 2008;68:10163-10170
37. Ballarè E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P, Faglia G, Spada A. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 2001; 86:3809-3814
38. Barz T, Hoffmann A, Panhuysen M, Spengler D. Peroxisome proliferator- activated receptor {gamma} is a zac target gene mediating zac antiproliferation. Cancer Res 2006;66:11975-11982 (Pubitemid 46094211)